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A B S T R A C T
Background
Tumor lysis syndrome (TLS) is a serious complication of malignancies and can result in renal failure or death. Preliminary reports
suggest that urate oxidase is highly effective in reducing serum uric acid. It is uncertain whether high quality evidence exists to support
its routine use in children with malignancies.
Objectives
Weaimed todetermine the effectiveness and safety of urate oxidase in the prevention and treatment ofTLS in childrenwithmalignancies.
Search strategy
We performed a comprehensive search of the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library issue
2, 2009), MEDLINE (1966 to 2009), EMBASE (1980 to 2009) and CINAHL (1982 to 2009).
Selection criteria
Randomized controlled trials (RCT) and controlled clinical trials (CCT) evaluating urate oxidase for the prevention or treatment of
TLS in children under 18 years with any malignancy.
Data collection and analysis
Two review authors independently extracted trial data and assessed individual trial quality. We used relative risk (RR) for binary data
and mean difference (MD) for continuous data.
Main results
We included five trials, involved 336 patients in the treatment groups and 458 patients in the control groups. One RCT and three
CCTs compared urate oxidase and allopurinol. Two trials tested Uricozyme and two tested rasburicase for the prevention of TLS. The
RCT showed no significant difference in mortality or renal failure between the treatment and the control groups. The frequency of
normalization of uric acid (RR 19.09, 95% CI 1.28 to 285.41) and area under curve of uric acid (MD -201, 95% CI to -258.05 to
-143.95) were significantly better in the treatment group. One patient developed hemolysis. One CCT reported significantly lower
mortality due to TLS (RR 0.05, 95% CI 0.00 to 0.89) and lower incidence of renal failure (RR 0.13, 95% CI 0.05 to 0.35) in the
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treatment group. Another CCT found significantly lower uric acid in the treatment group at 72 hours (MD -98.33, 95% CI -170.66
to -26) and 168 hours (MD -103.67, 95% CI -179.00 to -28.34). All included trials are highly susceptible to biases.
Another included RCT with 30 patients compared different doses of rasburicase (0.2 mg/kg versus 0.15 mg/kg), which demonstrated
similar efficacy in the reduction of uric acid. Adverse events occurred in 20% of patients, including hemolysis, hypersensitivity and
anemia.
Authors’ conclusions
Although urate oxidase might be effective in reducing serum uric acid, it is still unclear whether this translates into a reduction in
mortality or renal failure. Clinicians should weigh the potential benefits of reducing uric acid and uncertain benefits of preventing renal
failure or mortality from TLS against the potential risk of adverse effects.
P L A I N L A N G U A G E S U M M A R Y
Urate oxidase for the prevention and treatment of complications frommassive lysis (breakdown) of tumor cells in children with
cancer
Tumor lysis syndrome occurs when uric acid and other cellular substances are rapidly released into the circulation when tumor cells are
broken down spontaneously or during treatment. Uric acid has low solubility (does not dissolve easily), therefore it can build up in the
kidney resulting in kidney failure and possibly death eventually. Urate oxidase is an enzyme that can be administered to patients at risk
of tumor lysis syndrome to convert uric acid to a more soluble product, allantoin, which can be excreted by the kidneys more readily.
Therefore, urate oxidase may be able to prevent or treat tumor lysis syndrome in patients with malignancies. However, the current
systematic review of (randomized) controlled clinical trials found that although urate oxidase might be effective in reducing serum uric
acid level, it has not been shown to reduce renal failure or mortality from tumor lysis syndrome in children with cancer.
B A C K G R O U N D
Tumor lysis syndrome (TLS) is a serious complication of malig-
nancies that can occur spontaneously in the presence of rapidly
proliferating tumor cells or can occur during treatment because of
rapid cell lysis, leading to release of intracellular components that
may result in hyperkalemia, hyperphosphatemia, hypocalcemia
and hyperuricemia. Hyperuricemia and hyperphosphatemia can
result in crystallization in the renal tubules causing obstructive
uropathy and renal failure. Other severe consequences of tu-
mor lysis syndrome include cardiac arrhythmia and sudden death
fromhyperkalemia (Navolanic 2003; Rampello 2006). TheCairo-
Bishop definition for laboratory tumor lysis syndrome is the de-
velopment of any two or more of the following four criteria within
three days before or seven days after the initiation of chemother-
apy: uric acid level >= 8 mg/dL, potassium level >= 6 mmol/L,
phosphate level >= 6.65 mg/dL and calcium level <= 7mg/dL. A
25% increase from baseline for uric acid, potassium or phosphate
levels or a 25% decrease from baseline for calcium level is an al-
ternative threshold (Cairo 2004). The Cairo-Bishop definition for
clinical tumor lysis syndrome is the presence of laboratory tumor
lysis syndrome and one or more of the following three criteria:
serum creatinine level >= 1.5 times the upper limit of normal,
cardiac arrhythmias, sudden death or seizures.
Risk factors for tumor lysis syndrome include high proliferation
rate, large tumor burden and high chemosensitivity. High tumor
burden is indicated by a high white blood cell count in leukemia
(> 50 x 109/L) or a high lactate dehydrogenase level in lym-
phoma. Certain malignancies, such as Burkitt’s lymphoma, are
associated with a very high risk of tumor lysis syndrome because
of rapid tumor cell turnover (Wossmann 2003). The incidence
of tumor lysis syndrome varies among studies. A retrospective re-
view of acute lymphoblastic leukemia, acute myeloid leukemia
and non-Hodgkin’s lymphoma found that the frequency of tu-
mor lysis syndrome was 3.4%, 5.2% and 6.1% respectively, and
it accounts for 0.9% of cancer mortality (Annemans 2003a). The
mortality rate of tumor lysis syndrome has been estimated to be
about 17.5% (Annemans 2003a). The medical costs of hyper-
uricemia and tumor lysis syndrome are substantial. The cost of hy-
peruricemia without tumor lysis syndrome has been estimated to
be EURO672, and the cost of tumor lysis syndrome EURO7342
(Annemans 2003a). The cost of tumor lysis syndrome requiring
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dialysis has been shown to be even higher (EURO17,706 on av-
erage) (Annemans 2003a).
Aggressive hydration and allopurinol, with or without urinary al-
kalinization with bicarbonate, is the standard prophylaxis for tu-
mor lysis syndrome. Allopurinol is a xanthine oxidase inhibitor
which prevents the formation of uric acid but does not catabolize
existing uric acid. Allopurinol is therefore not an effective treat-
ment for established tumor lysis syndrome since it does not pro-
mote uric acid clearance. Due to the inhibition of xanthine oxi-
dase, allopurinol increases the level of uric acid precursors, hypox-
anthine and xanthine. As xanthine is less soluble than uric acid, it
may precipitate in renal tubules causing xanthine nephropathy or
xanthine stones (Greene 1969).
Urate oxidase is an alternative agent used for the treatment or pro-
phylaxis of hyperuricemia in patients who are at high risk of tu-
mor lysis syndrome. Urate oxidase converts uric acid to allantoin,
which is five to 10 times more soluble than uric acid and readily
excreted in urine. A non-recombinant form of urate oxidase has
been available in Europe for more than 20 years, but it is asso-
ciated with acute hypersensitivity reactions in 4.5% of patients
(Yim 2003). Rasburicase, a relatively new recombinant urate ox-
idase enzyme produced by a genetically modified Saccharomyces
cerevisiae strain, has now replaced the older agent and is widely
used. Reported advantages of urate oxidase over allopurinol in-
clude its ability to catabolize existing uric acid in established tu-
mor lysis syndrome, no increased risk of xanthine stone formation,
no requirement for dose adjustment in acute renal failure, lack of
clinically relevant drug-drug interaction, and lower incidence of
adverse reactions such as skin rash, fever, eosinophilia and Stevens
Johnson syndrome (Gutierrez 2005; Sanofi 2005). Anecdotal re-
ports and case series have indicated that urate oxidase may be ef-
fective in the prevention and treatment of tumor lysis syndrome
(Bosly 2003; Coiffier 2003; Hummel 2003; Hutcherson 2006;
Jeha 2005; Lascombes 1998; Lee 2003; Liu 2005; McDonnell
2006; Pui 1997; Pui 2001a; Pui 2001b; Shin 2006; Trifilio 2006;
Wang 2006), resulting in a significant reduction of serum uric
acid level and a low incidence of renal failure requiring dialysis.
In addition, the use of urate oxidase has been reported to be cost-
effective for the prevention and treatment of tumor lysis syndrome
in both children and adults (Annemans 2003b). However, it is
not entirely certain whether the existing evidence is sufficiently
rigorous to support the routine use of urate oxidase as prophylaxis
in children with malignancies at risk of tumor lysis syndrome, or
as a treatment for established laboratory or clinical tumor lysis
syndrome. It is also uncertain whether single or multiple doses of
urate oxidase should be used, or which types of high-risk patients
benefit most from prophylactic administration of urate oxidase.
Although there are consensus guidelines developed for the man-
agement of tumor lysis syndrome (Coiffier 2008; Tosi 2008), a rig-
orous systematic review of existing evidence is lacking. Therefore,
we examined the efficacy and safety of urate oxidase in children
with malignancies in a systematic review of randomized controlled
trials and controlled clinical trials.
O B J E C T I V E S
The objectives of this systematic review were to determine the ef-
fectiveness and safety of urate oxidase in children with malignan-
cies compared to other treatments. We aimed to determine:
1. whether urate oxidase is effective in preventing tumor lysis
syndrome;
2. whether urate oxidase is effective in preventing renal failure
or mortality associated with tumor lysis syndrome;
3. whether urate oxidase is effective in treating tumor lysis
syndrome;
4. whether urate oxidase administered to children with cancer
is associated with adverse effects.
The comparative effectiveness of different preparations and dif-
ferent doses of urate oxidase are also evaluated.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) in the review.
We also planned to include controlled clinical trials (CCTs) if no
(or few) RCTs were available. A CCT is a study that compares
one or more intervention groups to one or more control groups.
Historical controlled studies are included.
Types of participants
Patients under 18 years of age with all types of cancer including
hematological malignancies and solid tumors.
Types of interventions
We included trials evaluating all preparations of urate oxidase in
the review. The control interventions could be placebo, no treat-
ment or other treatment, such as allopurinol. We also included
trials comparing urate oxidase combined with other treatment ver-
sus the same other treatment alone, and trials comparing different
doses or different preparations of urate oxidase.
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Types of outcome measures
For evaluation of urate oxidase as prevention for tumor lysis syn-
drome, we used the following outcome measures.
Primary outcome
Incidence of clinical tumor lysis syndrome according to Cairo-
Bishop definition.
Secondary outcomes
1. Incidence of laboratory tumor lysis syndrome according to
Cairo-Bishop definition.
2. Mortality associated with tumor lysis syndrome and
combined with other reasons.
3. Incidence of renal failure requiring renal replacement
therapy associated with tumor lysis syndrome.
4. Frequency of normalization of serum uric acid level.
5. Duration before normalization of serum uric acid level.
6. Change in serum uric acid level.
7. Area under curve (AUC) of uric acid level.
8. Frequency of adverse effects.
For the evaluation of urate oxidase as treatment for tumor lysis
syndrome, we used the following outcome measures.
Primary outcome
Mortality associated with tumor lysis syndrome and combined
with other reasons.
Secondary outcomes
1. Incidence of renal failure requiring renal replacement
therapy associated with tumor lysis syndrome.
2. Frequency of normalization of serum uric acid level.
3. Duration before normalization of serum uric acid level.
4. Change in serum uric acid level.
5. Area under curve (AUC) of uric acid level.
6. Change in serum phosphate level.
7. Change in serum potassium level.
8. Change in serum creatinine level.
9. Change in serum calcium level.
10. Frequency of adverse effects.
Search methods for identification of studies
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library issue 2, 2009), MEDLINE
(1966 to August 2009), EMBASE (1980 to August 2009) and
CINAHL (1982 to August 2009).
The search strategies used for the different electronic databases (us-
ing a combination of controlled vocabulary and text word terms)
are shown in the Appendices (Appendix 1; Appendix 2; Appendix
3; Appendix 4).
We searched the reference lists of all identified relevant pa-
pers for further studies. We also explored other internet
sources: NHS National Research Register (http://www.update-
software.com/national); NIH Clinical Trials Database (http://
www.clinicaltrials.gov); metaRegister of Clinical Trials (http://
www.controlled-trials.com) and Digital Dissertations website (
http://wwwlib.umi.com/dissertations). We also handsearched ab-
stracts from the meetings of ASCO (American Society for Clinical
Oncology), ESMO (European Society forMedical Oncology) and
SIOP (International Society for Pediatric Oncology) from 1993
to 2009.
We also included articles published only in abstract form if the
authors could be contacted to provide essential details for appraisal
and analysis. If the process of searching many different sources
brought to light direct or indirect references to unpublished stud-
ies, we planned to obtain copies of such unpublished material.
In addition, we contacted colleagues and experts in the field to
ascertain any unpublished or ongoing studies. We also contacted
themanufacturer of rasburicase, Sanofi-Aventis, for published and
unpublished clinical studies.
There was no language restriction in the search and inclusion of
studies. However, we excludedmultiple publications reporting the
same group of patients or its subsets.
Data collection and analysis
Selection of studies
Two authors (first and second authors) independently reviewed
titles and abstracts of references retrieved from the searches and
selected all potentially relevant studies. The same authors obtained
copies of these articles and reviewed them independently against
the inclusion and exclusion criteria for study selection mentioned
above. Authors were not blinded to the names of the trial authors,
institutions or journal of publication. The third author was to re-
solve any discrepancies between the two authors regarding selec-
tion of studies.
Data extraction and management
Two authors extracted data from included trials independently.
The third author was to resolve any discrepancies regarding data
extraction.
The following data were extracted.
1. Study methods:
i) design (i.e. RCT or CCT);
ii) randomization method (including list generation);
iii) method of allocation concealment;
iv) blinding method;
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v) stratification factors.
2. Participants:
i) inclusion/exclusion criteria;
ii) number of patients entering the trial, number of
patients randomized, number of excluded patients (with reasons)
and number of evaluable patients;
iii) age and gender distribution;
iv) type of malignancies;
v) treatments for the malignancies (chemotherapy,
radiotherapy, autologous stem cell transplant, allogeneic stem
cell transplant);
vi) baseline renal function, uric acid level, potassium level,
phosphate level, calcium level, lactate dehydrogenase (LDH)
level, white blood cell (WBC) counts (for leukemia), rate of
decrease of WBC (for leukemia), and sizes of the liver and spleen.
3. Intervention and control:
i) type of uric oxidase;
ii) type of control treatment;
iii) details of administration of urate oxidase, including
dosage and schedules;
iv) details of co-interventions.
4. Follow-up data:
i) duration of follow up
ii) loss to follow up
5. Outcome data:
i) serial uric acid levels measurement;
ii) days to normalization of uric acid level;
iii) number of criteria of laboratory tumor lysis syndrome
according to Cairo-Bishop definition;
iv) number of criteria of clinical tumor lysis syndrome
according to Cairo-Bishop definition;
v) change in serum potassium, calcium, phosphorus and
creatinine levels;
vi) adverse effects.
6. Analysis data:
i) methods of analysis (intention-to-treat or per-protocol
analysis);
ii) comparability of groups at baseline (yes/no);
iii) statistical methods.
One author entered the data into Review Manager (RevMan) (
RevMan 2008); the other authors then checked the data.
Assessment of risk of bias in included studies
Two authors (first and second authors) independently assessed
the methodological quality of each eligible trial. The third author
was to resolve any discrepancies regarding methodological qual-
ity. Where necessary, we sought additional information from the
principal investigator of the trial concerned.
We included the following items to assess themethodological qual-
ity of RCTs.
Selection bias
Allocation concealment:
A. Adequate
Use of randomization method that did not allow investigator and
participant to know or influence the allocation of treatment before
eligible participants entered the study.
B. Unclear
Randomization stated but no information on method used was
available.
C. Inadequate
Use of alternate medical record numbers or unsealed envelopes as
randomization method and/or there was information in the study
indicating that investigators or participants could have influenced
the allocation of treatment.
Performance bias
Blinding of care providers: Yes/No/Unclear
Blinding of participants: Yes/No/Unclear
Care providers and patients were considered not blinded if the
intervention group could be identified in > 20% of participants
because of the side effects of treatment.
Detection bias
Blinding of outcome assessors: Yes/No/Unclear
Attrition bias
Intention-to-treat analysis:
A. Yes
All participants were analysed in the treatment group to which
they were allocated, regardless of whether of not they received the
allocated intervention.
B. No
Some participants (< 5%, 5% to 10%, 10% to 20%, > 20%)
were not analyzed in the treatment group to which they were
randomized because they did not receive study intervention, they
withdrew from the study, or because of protocol violation.
C. Unclear
Unable to determine if patients were analyzed according to the
intention-to-treat principle after contact with the authors.
Completeness of follow up
Percentage of participants excluded or lost to follow up for the dif-
ferent treatment groups for the primary and secondary outcomes
(< 5%, 5% to 10%, 10% to 20%, > 20%).
We assessed controlled clinical trials similarly for the above men-
tioned types of biases. They were expected not to incorporate ran-
dom allocation of treatment groups, or perform allocation con-
cealment. Due to non-random treatment group allocation, they
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were also susceptible to confounding and we examined possible
confounding factors, including age of the patient, types of malig-
nancies, baseline renal function, white blood cell (WBC) counts,
lactate dehydrogenase (LDH) level, uric acid levels and intensity
of chemotherapy.
Measures of treatment effect
We used relative risk (RR) estimations with 95% confidence in-
tervals (CI) for binary outcomes. We used mean difference esti-
mations (MD) with 95% CI for continuous outcomes. All anal-
yses included all participants in the treatment groups to which
they were allocated (intention-to-treat analyses). We planned to
perform per protocol analyses if information for intention-to-treat
analyses was lacking. We planned to consider cost-effectiveness of
interventions if relevant data were available.
Dealing with missing data
We contacted the authors of included studies to supply missing
data. We assessed missing data and drop-outs/attrition for each
included study, and assessed and discussed the extent to which the
results/conclusions of the review could be altered by the missing
data. If, for a particular outcome, less than 70% of patients allo-
cated to the treatments were reported on at the end of the trial,
those data would not be used as they were considered to be too
prone to bias. However, none of the included studies had out-
comes with < 70% of subjects reported and therefore all available
data were used.
Assessment of reporting biases
We planned to generate a funnel plot (effect size against standard
error) if sufficient studies (more than five) were found. Asymme-
try could be due to publication bias, but could also be due to a
relationship between trial size and effect size. In the event that a
relationship was found, we planned to examine clinical diversity
of the studies (Egger 1997).
Data synthesis
Where the interventions were the same or similar enough, we
planned to synthesize results in a meta-analysis if there was no im-
portant clinical heterogeneity. If no significant statistical hetero-
geneity was present, the data would be synthesized using a fixed-
effect model. If there was unexplained heterogeneity, we would
use a random-effects model in the meta-analysis.
Subgroup analysis and investigation of heterogeneity
If data permitted, we planned to conduct subgroup analyses for:
1. different types of malignancies (acute leukemia, lymphoma,
solid tumor);
2. different number of doses of urate oxidase (single dose, two
doses, three or more doses);
3. different levels of risk of tumor lysis syndrome (patients
with rapid cell turnover, high lactate dehydrogenase (LDH) or
baseline hyperuricemia).
If two or more included trials reported the same outcomes for the
same subgroups, we planned to combine their results inmeta-anal-
yses if no significant heterogeneity was present. We assessed clini-
cal heterogeneity by comparing the distribution of important par-
ticipant factors between trials (age, type of malignancies) and trial
factors (randomization concealment, blinding of outcome assess-
ment, losses to follow up, treatment regimens). We assessed statis-
tical heterogeneity of RCTs by examining the I2 statistic (Higgins
2002), a quantity which describes approximately the proportion
of variation in point estimates that is due to heterogeneity rather
than sampling error. If significant heterogeneity is present (i.e. I2
>= 50% (Higgins 2009), we planned to explore the trials to inves-
tigate possible explanations.
Sensitivity analysis
We planned to conduct sensitivity analyses to assess the impact of
study quality, including:
1. all studies;
2. only those studies with adequate allocation concealment.
We also planned to conduct sensitivity analyses to assess the impact
of heterogeneity, by excluding those with outlying results.
R E S U L T S
Description of studies
See: Characteristics of included studies.
The electronic searches retrieved 68 articles fromMEDLINE. We
excluded 64 based on title or abstract, because of obvious irrele-
vance. We examined full texts for the four remaining articles. Two
were randomized controlled trials (RCTs) satisfying the inclusion
criteria (Goldman 2001; Kikuchi 2009) and the other two were
controlled clinical trials (CCTs) (Renyi 2007; Wossmann 2003).
We included these two CCTs in the review because there were
only two RCTs identified.We also retrieved 100 articles fromEM-
BASE. All but two were excluded after examining the title and
abstract. These two articles were also identified in the MEDLINE
search (Kikuchi 2009; Renyi 2007). We retrieved 17 articles from
CENTRAL. We excluded 16 based on title or abstract and in-
cluded one. This was one of the RCTs identified in MEDLINE
(Goldman 2001). We retrieved 40 articles from CINAHL. We
excluded 37 based on title or abstract. The remaining three arti-
cles were the same as those identified from MEDLINE and were
included (Goldman 2001; Renyi 2007; Wossmann 2003). One
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more CCT (Patte 2002) was identified and included after check-
ing the reference lists of the other included studies. We identified
no additional completed or ongoing trials on checking internet
sources and conference proceedings and contacting experts. There
was no discrepancy in the independent selection of included stud-
ies among the two authors and a third author was not necessary
in this process.
All five included trials evaluated urate oxidase as a preventive mea-
sure for tumor lysis syndrome. No clinical trial investigating urate
oxidase for treatment of tumor lysis syndrome was identified. De-
tails of the five included trials are given in the table ’Characteristics
of included studies’ and are summarized below.
Four included trials compared urate oxidase against allopurinol as
the control treatment in parallel group designs (Goldman 2001;
Patte 2002; Renyi 2007; Wossmann 2003). The remaining in-
cluded trial compared different doses of urate oxidase (Kikuchi
2009). Rasburicase was used in three trials (Goldman 2001;
Kikuchi 2009; Renyi 2007) while Uricozyme was used in the re-
maining two trials (Patte 2002; Wossmann 2003). A standard al-
kaline hyperhydration regimen was also used in both the inter-
vention and the control groups in three included trials (Goldman
2001; Patte 2002; Renyi 2007), while alkalinization was used only
in the control group in one trial (Wossmann 2003) and not men-
tioned in the remaining trial (Kikuchi 2009). The interventions
in all trials were initiated before the start of chemotherapy and
lasted for five to seven days.
None of the three included non-randomized controlled clinical
trials used a concurrent control group. Two trials used a historical
control group (Renyi 2007; Wossmann 2003) and one trial used
aggregate patient data from trials of other study groups as a retro-
spective analysis (Patte 2002).
The RCT by Goldman included 27 patients aged 0.3 to 17 years
in the intervention group and 25 patients aged 0.5 to 16 years
in the control group (Goldman 2001). The patients were strati-
fied into hyperuricemic and normouricemic groups for random-
ization. The RCT by Kikuchi included 30 patients with a median
age of 11 years in the group receiving 0.15 mg/kg/day and 30
patients with median age of seven years receiving 0.2 mg/kg/day.
The three controlled clinical trials included a total of 294 patients
in the intervention group and 418 patients in the control groups.
In one of the three trials, the median age of the patients was 4.5
years in the intervention group and six years in the control group
(Renyi 2007). The age distribution of the patients was not men-
tioned in the remaining two trials (Patte 2002; Wossmann 2003).
The types of malignancies included in all four trials were similar.
The RCT by Goldman recruited patients with stage 3 or 4 non-
Hodgkin’s lymphoma, acute lymphoblastic leukemia (ALL) with
high white blood cell (WBC) counts, or patients with leukemia
or lymphoma with hyperuricemia (Goldman 2001). The RCT by
Kikuchi recruited patients with hyperuricemia or patients with a
high tumor burden, including stage 4 non-Hodgkin’s lymphoma,
stage 3 non-Hodgkin’s lymphoma with large lymph node or high
lactate dehydrogenase (LDH), or acute leukemia with high WBC
(Kikuchi 2009). All the three controlled clinical trials included
patients with stage 3 or 4 non-Hodgkin’s lymphoma or B cell ALL
at high risk of tumor lysis syndrome, with just minor differences in
the inclusion criteria among these trials (for details please refer to
’Characteristics of included studies’ table). The RCT by Goldman
reported baseline serum creatinine, uric acid, potassium, phos-
phate, calcium, LDH andWBC levels of the intervention and the
control groups (Goldman 2001). The RCT by Kikuchi only re-
ported baseline creatinine, without mentioning baseline uric acid
or other electrolyte concentrations (Kikuchi 2009), although the
number of patients with hyperuricemia at baseline was reported.
One of the controlled clinical trials reported baseline serum crea-
tinine, uric acid, phosphate, LDH and WBC levels (Renyi 2007),
while one controlled clinical trial did not report any of these base-
line data (Wossmann 2003) and one trial just reported the number
of patients with renal failure or elevated LDH in the intervention
group only (Patte 2002).
The RCT by Goldman used area under curve (AUC) of serum
uric acid at 96 hours as the primary outcome measure (Goldman
2001), while the RCT by Kikuchi used response rate as the pri-
mary outcome measure, which was defined as the plasma uric acid
<= 7.5 mg/dL (or <= 6.5 mg/dL in patients < 13 years) by 48
hours and lasting until 24 hours after the last dose of rasburicase
(Kikuchi 2009). The RCT by Goldman also reported mortality
and incidence of renal failure and frequency of normalization of
serum uric acid level (Goldman 2001). On the other hand, the
RCTbyKikuchi reported secondary outcomes of changes in serum
creatinine. The outcomes used for the three included controlled
clinical trials were variable. All three trials reported the incidence
of renal failure, while two trials reported all-cause mortality (Renyi
2007; Wossmann 2003) and one trial reported mortality due to
tumor lysis syndrome (Patte 2002). Only one trial reported the
incidence of tumor lysis syndrome, which was not clearly defined
(Wossmann 2003). One trial reported mean serum uric acid levels
serially (Renyi 2007).
Risk of bias in included studies
In general none of the included trials were of high methodolog-
ical quality. Both randomized controlled trials were quite small,
recruiting only 52 patients and 30 patients in total, respectively
(Goldman 2001; Kikuchi 2009). Randomization concealment ap-
peared adequate in the trial by Goldman as the randomization
code was computer-generated (Goldman 2001). However, ran-
domization concealmentwas notmentioned in the trial byKikuchi
(Kikuchi 2009). There was no blinding of participants or care
providers or outcome assessors in either trial, which might intro-
duce performance and detection biases. The treatment duration
in the trial by Goldman varied from five to seven days, subject
to clinician’s discretion, which might introduce bias (Goldman
2001). Both trials used intention-to-treat analyses for available
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data. There was one drop-out in the intervention group (3.7%)
and three drop-outs in the control group (12%) in the trial by
Goldman (Goldman 2001); and one drop-out in the high-dose
group (6.7%) in the trial by Kikuchi (Kikuchi 2009). These drop-
outs might introduce attrition bias. Furthermore, comparability of
the intervention and the control groups was questionable in both
trials. In the trial by Goldman, serum uric acid level was higher in
the treatment group compared to the control group. This raises
doubts about the validity and reliability of the randomization pro-
cess. In the trial by Kikuchi, median body weight was higher in
the low-dose group, and baseline hyperuricemia and diagnosis of
lymphoma were more frequent in the low-dose group (Kikuchi
2009). All these factors may affect the validity of the results based
on direct comparisons of outcomes between the groups without
adjusting for confounders.
The three included controlled clinical trials were also not of good
methodological quality in general. Since patients in these trials
were not randomly assigned to treatment and control groups, there
might have been selection bias. This is evident in two of the trials
in which the treatment and the control groups were not compara-
ble at baseline. In one trial the treatment group had more patients
with lymphoma, higher uric acid level, lower LDH level and lower
serum creatinine and phosphorus than the control group (Renyi
2007). In another trial the treatment group had fewer patients
who were critically ill or had complications after initial surgery
(Wossmann 2003). The remaining trial did not report important
baseline characteristics of the treatment and the control groups
and therefore the comparability of the two groups could not be
ascertained (Patte 2002). There was no blinding of care providers,
patients or outcome assessors any of the three CCTs. Intention-to-
treat analysis was performed in all three CCTs in all evaluable pa-
tients with available data. Missing outcome data were not imputed
for analyses. Follow up was complete for all reported outcome data
in two trials (Patte 2002; Wossmann 2003). In one trial, follow
up was incomplete and serum uric acid data at 24 to 288 hours
post-treatment were missing in six to 12 patients (43% to 86%)
(Renyi 2007). The large proportion of missing data may cause sig-
nificant bias. The results of non-randomized controlled trials are
susceptible to confounding by known or unknown confounding
factors. However, none of the included controlled clinical trials
attempted to adjust the results for potential known confounding
factors. The results from simple unadjusted comparisons between
the treatment and the control groups might not be valid. More-
over, the treatment duration was variable in all three trials, de-
pending on clinicians’ judgment, which might introduce biases.
In addition, the use of historical controls in two trials is problem-
atic, as improvement in supportive care over the years might have
biased the results in favor of the newer treatment modality (Renyi
2007; Wossmann 2003).
Effects of interventions
Urate oxidase versus allopurinol
Randomized controlled trial (RCT)
The RCT recruited only 52 patients in total. It did not report our
pre-determined primary outcome of incidence of tumor lysis syn-
drome (Goldman 2001). Intention-to-treat analyses were used for
all outcome data. This trial showed no mortality related to tumor
lysis syndrome in either the treatment or the control group (Figure
1). There was no death in the treatment group. There were two
deaths (8%) in the control group; the patients died from Pseu-
domonas sepsis and intracerebral hemorrhage respectively (Figure
2). None of the patients in the treatment group developed renal
failure but one patient in the control group developed renal fail-
ure (Figure 3). The frequency of normalization of serum uric acid
level was significantly higher in hyperuricemic patients receiving
rasburicase (RR 19.09, 95% CI 1.28 to 285.41) (Figure 4). The
area under curve of serum uric acid level at 96 hours was also
significantly lower in the treatment group (MD -201, 95% CI -
258.05 to -143.95) (Figure 5).
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Figure 1. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.4 Mortality
due to tumor lysis syndrome.
Figure 2. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.3 All-cause
mortality.
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Figure 3. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.5 Renal failure
requiring renal replacement therapy.
Figure 4. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.7
Normalization of serum uric acid level at 4 hours.
Figure 5. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.8 AUC of
serum uric acid level at 96 hours.
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For subgroup analyses, the area under curve of serum uric acid
level at 96 hours was significantly lower in the treatment group
compared to the control group in subgroups of patients with
leukemia (MD -220, 95% CI -286.67 to -153.33) (Figure 6),
lymphoma (MD -132, 95% CI -185.47 to -78.53) (Figure 7), pa-
tients who were hyperuricemic (MD -278, 95% CI -335.68 to -
220.32) (Figure 8), or who were normouricemic (MD -240, 95%
CI -320.72 to -159.28) (Figure 9).
Figure 6. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.9 AUC of
serum uric acid level at 96 hours in leukemia patients.
Figure 7. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.10 AUC of
serum uric acid level at 96 hours in lymphoma patients.
Figure 8. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.11 AUC of
serum uric acid level at 96 hours in hyperuricemic patients.
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Figure 9. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.12 AUC of
serum uric acid level at 96 hours in normouricemic patients.
For adverse events, the trial by Goldman reported that one patient
in the treatment group developed hemolysis and that there were
no adverse effects reported in the control group (Goldman 2001)
(Figure 10).
Figure 10. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.19 Frequency
of adverse events.
Since only one RCTwas identified for this comparison, we did not
perform sensitivity analysis and assessment for publication bias.
Since no high quality data on effectiveness were identified, we did
not perform a cost-benefit analysis.
Controlled clinical trials
Intention-to-treat analyses were used for all outcomes in all three
CCTs. One trial reported the incidence of clinical tumor lysis
syndrome (Wossmann 2003), which was lower in the treatment
group, but did not reach statistical significance (RR 0.77, 95% CI
0.44 to 1.33) (Figure 11). This trial also reported treatment-related
mortality from all causes, without specifying the actual cause of
death or whether is might be related to tumor lysis syndrome.
There were no deaths in the treatment group but four deaths in
the control group, a difference that was not statistically significant
(Figure 2). One trial reported mortality related to tumor lysis
syndrome (Patte 2002). In this trial, mortality due to tumor lysis
syndrome was 0% in the treatment group but 5.9% in the control
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group, which represented a statistically significant difference (RR
0.05, 95% CI 0.00 to 0.89) (Figure 1). All three trials reported the
incidence of renal failure due to tumor lysis syndrome but there
was no statistically significant difference between the treatment
and the control groups, except for the trial by Patte, in which the
treatment group had a lower incidence of renal failure (RR 0.13,
95% CI 0.05 to 0.35) (Patte 2002) (Figure 3). As the three trials
were heterogeneous, we did not make a pooled estimate. The trials
evaluated different types of urate oxidase (Uricozyme used in two
trials and rasburicase used in one trial) with different doses and
regimens of treatment. They also had different subject inclusion
and exclusion criteria, and different composition of subjects in
terms of distribution of underlying malignancies.
Figure 11. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.1 Incidence of
clinical tumor lysis syndrome.
One trial reported serial serum uric acid levels and found sig-
nificantly lower serum uric acid levels in the treatment group at
72 hours (MD -98.33, 95% CI -170.66 to -26) and 168 hours
(MD -103.67, 95% CI -179.00 to -28.34), but not at other hours
(Renyi 2007) (Figure 12; Figure 13; Figure 14; Figure 15; Figure
16; Figure 17).
Figure 12. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.13 Serum
uric acid level at 24 hours.
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Figure 13. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.14 Serum
uric acid level at 48 hours.
Figure 14. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.15 Serum
uric acid level at 72 hours.
Figure 15. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.16 Serum
uric acid level at 120 hours.
14Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 16. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.17 Serum
uric acid level at 168 hours.
Figure 17. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.18 Serum
uric acid level at 288 hours.
For subgroup analyses, Wossmann reported the frequency of tu-
mor lysis syndrome and the frequency of renal failure in patients
with B cell acute lymphoblastic leukemia, which were both lower
in the treatment group but the differences did not reach statistical
significance (Wossmann 2003) (Figure 18; Figure 19).
Figure 18. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.2 Incidence of
clinical tumor lysis syndrome in B-ALL subgroup.
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Figure 19. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.6 Renal
failure requiring renal replacement therapy in B-ALL subgroup.
No adverse events were reported by the CCTs.
Higher versus lower doses of urate oxidase
There was only one RCT comparing different doses of rasburic-
ase (0.2 mg/kg daily for five days versus 0.15 mg/kg daily for five
days) (Kikuchi 2009). There was only one death reported, which
occurred in the low-dose group and was due cerebral hemorrhage,
brain edema and brain herniation. There was no significant differ-
ence in mortality between the two treatment groups (Figure 20;
Figure 21). The frequency of normalization of serum uric acid was
slightly higher in the high-dose group (100% versus 93.3%), but
not statistically significant (RR1.07, 95%CI 0.89 to 1.28) (Figure
22). Mean percentage reduction in plasma uric acid level was also
slightly higher in the high-dose group at four hours (92.9% versus
84.8%), but the difference was not statistically significant (MD
8.1%, 95% CI -0.99 to 17.19) (Figure 23).
Figure 20. Forest plot of comparison: 2 High-dose rasburicase compared to low-dose rasburicase, outcome:
2.1 Mortality due to tumor lysis syndrome.
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Figure 21. Forest plot of comparison: 2 High-dose rasburicase compared to low-dose rasburicase, outcome:
2.2 All-cause mortality.
Figure 22. Forest plot of comparison: 2 High-dose rasburicase compared to low-dose rasburicase, outcome:
2.3 Normalization of serum uric acid.
Figure 23. Forest plot of comparison: 2 High-dose rasburicase compared to low-dose rasburicase, outcome:
2.4 Percentage reduction in serum uric acid level at 4 hours.
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Drug-related adverse effects occurred in six patients (two in the
high-dose group and four in the low-dose group). There was no
statistically significant difference in the frequency of adverse events
between the high-dose and the low-dose groups (RR 0.5, 95% CI
0.11 to 2.33) (Figure 24).
Figure 24. Forest plot of comparison: 2 High-dose rasburicase compared to low-dose rasburicase, outcome:
2.5 Frequency of adverse events.
One patient in the high-dose group experienced grade 3 hemoly-
sis. This patient did not have glucose-6-phosphate dehydrogenase
(G6PD) deficiency. One patient in the low-dose group experi-
enced grade 1 hypersensitivity and another patient in the low-dose
group experienced grade 3 anemia. The types of adverse effects in
the remaining three patients were not mentioned.
Since there was only one RCT identified, we did not perform sen-
sitivity analysis and assessment for publication bias. Since no high
quality data on effectiveness were identified, we did not perform
a cost-benefit analysis.
D I S C U S S I O N
Although numerous uncontrolled studies have found that urate
oxidase can lower serum uric acid levels quickly and sometimes
dramatically, we found little evidence from randomized controlled
trials (RCTs) or controlled clinical trials (CCTs) supporting its
effectiveness in preventing or treating tumor lysis syndrome in
children. Only two randomized controlled trials and three con-
trolled clinical trials were available on the prophylaxis of tumor
lysis syndrome. There is currently no trial evaluating urate oxidase
for treatment of established tumor lysis syndrome. The RCTs on
prophylaxis of tumor lysis syndrome did not report the incidence
of clinical or biochemical tumor lysis syndrome after treatment
(Goldman 2001; Kikuchi 2009).
Urate oxidase versus allopurinol
Although patients who received rasburicase had significantly lower
exposure to hyperuricemia compared to patients who received al-
lopurinol in the trial by Goldman (Goldman 2001), we were not
entirely certainwhether this translated into significant clinical ben-
efits. Although hyperuricemia is related to tumor lysis syndrome,
this trial failed to show any significant difference between the treat-
ment and the control groups in all-cause mortality or mortality
related to tumor lysis syndrome, and this might be related to the
small sample size. Apart from inadequate power to detect clinically
relevant outcomes, this RCT had a number of methodological
flaws and was prone to bias. The treatment and the control groups
were not comparable at baseline, which casts doubt on the success
of randomization (although this might not have affected the con-
clusion on its effectiveness in reducing serum uric acid level, as the
higher baseline serum uric acid level in the treatment group should
have biased the results in favor of the control group). This trial did
not blind patients, physicians or outcome assessors which might
introduce performance and detection biases. Although there were
few drop-outs (7.7%), more drop-outs occurred in the control
arm than in the treatment arm which might cause attrition bias.
In view of all these limitations, the results and conclusions of this
trial should be treated with caution.
Due to the paucity of evidence from randomized controlled trials,
we also included controlled clinical trials in the current systematic
review. However, all three CCTs identified (including two histor-
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ical controlled studies) were also of unsatisfactory methodological
quality. Moreover, because the search was focused on RCTs and
CCTs we could have missed some further historical controlled tri-
als. One of the trials included only 28 patients and suffered simi-
larly from insufficient statistical power (Renyi 2007). The results
from the two historical controlled trials (Renyi 2007; Wossmann
2003) were prone to bias from the advancement of supportive
care with time. The remaining trial (Patte 2002) was actually a
retrospective review of data from trials of chemotherapy proto-
cols comparing different treatments from different study groups
at different locations, and therefore suffers from data insufficiency
and bias due to different practices in different centers. None of
the three CCTs took into consideration and adjusted for poten-
tial confounding factors in their analyses, and hence their results
were susceptible to confounding by known and unknown factors.
Although mortality due to tumor lysis syndrome and incidence
of renal failure were reported to be significantly lower in patients
who received Uricozyme in one trial (Patte 2002), the conclusion
of this trial should be treated with caution in view of the potential
biases.
On the other hand, due to inadequate sample size in the existing
trials, especially of high-risk patients, the absence of significant
clinical benefits of urate oxidase may be a false negative result.
Therefore, the potential benefits of urate oxidase in children with
malignancy cannot be excluded based on the current available
evidence, especially in view of its probable effectiveness in reducing
serumuric acid, which is an important surrogate outcome. Further
trials of larger sample size are needed to clarify the role of urate
oxidase. Assuming a mortality rate of 0.9% (Annemans 2003a)
and that urate oxidase is effective in reducing mortality by half,
the number of cancer patients needed to treat to prevent one death
is 223, and the sample size required to achieve a power of 80% in
detecting a reduction in mortality at a 5% level of significance is
estimated to be 856 patients.
Although not eligible for inclusion in this review, there is a study
that has addressed the cost-effectiveness of rasburicase (Annemans
2003b). This study concluded that rasburicase was cost-effective
for preventionof tumor lysis syndrome in children, and rasburicase
for the treatment of tumor lysis syndrome in children was cost-
saving.However, this conclusionwas based on the assumption that
rasburicase is 60% to 100% effective in the prevention of tumor
lysis syndrome, which was not in fact based on high quality trial
evidence. As the effectiveness of urate oxidase in the prevention
or treatment of tumor lysis syndrome has yet to be established, its
cost-effectiveness remains uncertain.
Higher versus lower doses of urate oxidase
There was only one RCT comparing different doses of rasburic-
ase. The results were consistent with previous uncontrolled studies
and controlled clinical trials; comparing rasburicase at 0.15 mg/
kg and 0.2 mg/kg showed a dramatic reduction in serum uric acid
level in both arms, but again this small trial was not adequately
powered to address the clinically important outcomes of mortality
or renal failure (Kikuchi 2009). Although there was no significant
difference in any of the outcomes between the two groups, we are
not certain whether higher and lower-dose rasburicase are really
equivalent because of the small sample size. Likewise, there is un-
certainly about whether the higher dose is associated with more
adverse effects.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Thus far the paucity of high quality studies precludes firm rec-
ommendations. Although there is some evidence that urate ox-
idase might be more effective than allopurinol in reducing the
frequency of hyperuricemia and reducing the exposure to high-
serumuric acid, it is still uncertain whether the routine use of urate
oxidase is effective for the prevention or treatment of tumor lysis
syndrome, or a reduction in mortality or renal failure associated
with tumor lysis syndrome in children with cancer. The poten-
tial benefit of urate oxidase might be its effectiveness in reducing
serum uric acid, which is an important surrogate outcome. It is
unclear which type of urate oxidase (rasburicase or Uricozyme) is
superior in terms of efficacy, and what dosage regimen or treat-
ment duration is optimal. On the other hand, urate oxidase may
be associated with potential adverse effects such as hemolysis or
hypersensitivity. Clinicians who wish to use urate oxidase should
weigh the potential benefits of reducing serum uric acid levels and
the uncertain benefits in preventing renal failure or mortality from
tumor lysis syndrome against the potential risk of adverse effects.
Implications for research
There is a paucity of evidence from randomized controlled trials
assessing urate oxidase for the prevention and treatment of tumor
lysis syndrome in children with cancer. The existing trials are of
small size and low methodological quality. Further high quality
RCTs of larger sample size are needed to assess the effectiveness
of urate oxidase in children, especially high-risk patients who are
more likely to benefit. Trials should assess patient-orientated out-
comes such as incidence of clinical tumor lysis syndrome, mortal-
ity or frequency of renal failure. Although blinding of patients and
clinicians for comparison of intravenous urate oxidase and oral al-
lopurinol is difficult, it can be attempted with the use of a double
placebo, to minimize performance biases. The effectiveness and
safety of different forms of urate oxidase in different dosage regi-
mens should also be investigated further.
A C K N OW L E D G E M E N T S
19Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We are grateful to Dr Edit Bardi for providing us with missing
data on the trial his group has published (Renyi 2007) and Dr
Edith Leclercq for helping with the development of the search
strategy and for the electronic search of the databases MEDLINE,
EMBASE and CENTRAL.
The editorial base of the Cochrane Childhood Cancer Group is
funded by Kinderen Kankervrij (KIKA).
R E F E R E N C E S
References to studies included in this review
Goldman 2001 {published data only}
Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson
R, Kreissman S, Johnson FL, et al.A randomized comparison
between rasburicase and allopurinol in children with
lymphoma or leukemia at high risk for tumor lysis. Blood
2001;97:2998–3003.
Kikuchi 2009 {published data only}
Kikuchi A, Kigasawa H, Tsurusawa M, Kawa K, Kikuta A,
Tsuchida M, et al.A study of rasburicase for the management
of hyperuricemia in pediatric patients with newly diagnosed
hematologic malignancies at high risk for tumor lysis
syndrome. International Journal of Hematology 2009;90(4):
492–500.
Patte 2002 {published data only}
Patte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier
E, Pacquement H, et al.Urate-oxidase in the prevention
and treatment of metabolic complications in patients with
B-cell lymphoma and leukemia, treated in the Société
Francaise d’Oncologie Pediatrique LMB89 protocol. Annals
of Oncology 2002;13:789–95.
Renyi 2007 {published data only}
Renyi I, Bardi E, Udvardi E, Kovacs G, Bartyik K, Kajtar
P, et al.Prevention and treatment of hyperuricemia with
rasburicase in children with leukemia and non-Hodgkin’s
lymphoma. Pathology Oncology Research 2007;13:57–62.
Wossmann 2003 {published data only}
Wossmann W, Schrappe M, Meyer U, Zimmermann M,
Reiter A. Incidence of tumor lysis syndrome in children
with advanced stage Burkitt’s lymphoma/leukemia before
and after introduction of prophylactic use of urate oxidase.
Annals of Hematology 2003;82(3):160–5.
Additional references
Annemans 2003a
Annemans L, Moeremans K, Lamotte M, Garcia Conde
J, van den Berg H, Myint H, et al.Incidence, medical
resource utilisation and costs of hyperuricemia and tumour
lysis syndrome in patients with acute leukaemia and non-
Hodgkin’s lymphoma in four European countries. Leukemia
Lymphoma 2003;44(1):77–83.
Annemans 2003b
Annemans L, Moeremans K, Lamotte M, Garcia Conde J,
van den Berg H, Myint H, et al.Pan-European multicentre
economic evaluation of recombinant urate oxidase
(rasburicase) in prevention and treatment of hyperuricaemia
and tumour lysis syndrome in haematological cancer
patients. Supportive Care in Cancer 2003;11(4):249–57.
Bosly 2003
Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D,
Sanz MA, et al.Rasburicase (recombinant urate oxidase) for
the management of hyperuricemia in patients with cancer:
report of an international compassionate use study. Cancer
2003;98(5):1048–54.
Cairo 2004
Cairo MS, Bishop M. Tumour lysis syndrome: new
therapeutic strategies and classification. British Journal of
Haematology 2004;127(1):3–11.
Coiffier 2003
Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet
A, et al.Efficacy and safety of rasburicase (recombinant urate
oxidase) for the prevention and treatment of hyperuricemia
during induction chemotherapy of aggressive non-
Hodgkin’s lymphoma: results of the GRAAL1 (Groupe
d’Etude des Lymphomes de l’Adulte Trial on Rasburicase
Activity in Adult Lymphoma) study. Journal of Clinical
Oncology 2003;21(23):4402–6.
Coiffier 2008
Coiffier B, Arnold A, Pui CH, Younes A, Cairo M.
Guidelines for the management of pediatric and adult
tumor lysis syndrome: an evidence-based review. Journal of
Clinical Oncology 2008;26:2767–78.
Egger 1997
Egger M, Davey-Smith G, Schneider M, Minder C. Bias in
meta-analysis detected by a simple, graphic test. BMJ 1997;
315(7):629–34.
Greene 1969
Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine
stones - a rare complication of allopurinol therapy. New
England Journal of Medicine 1969;280:626–7.
Gutierrez 2005
Gutierrez-Macias A, Lizarralde-Palacios E, Martinex-
Odriozola P, Miguel-De la Villa F. Fatal allopurinol
20Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
hypersensitivity syndrome after treatment of asymptomatic
hyperuricemia. BMJ 2005;331:623–4.
Higgins 2002
Higgins JP, Thompson SG. Quantifying heterogeneity in a
meta-analysis. Statistics in Medicine 2002;21:1539–58.
Higgins 2009
Higgins JPT, Green S, editors. Cochrane Handbook for
Systematic Reviews of Interventions 5.0.2 [updated September
2009]. The Cochrane Collaboration, 2009.
Hummel 2003
Hummel M, Buchheidt D, Reiter S, Bergmann J, Hofheinz
R, Hehlmann R. Successful treatment of hyperuricemia
with low doses of recombinant urate oxidase in four patients
with hematologic malignancy and tumor lysis syndrome.
Leukemia 2003;17(12):2542–4.
Hutcherson 2006
Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M.
Reduced-dose rasburicase in the treatment of adults with
hyperuricemia associated with malignancy. Pharmacotherapy
2006;26(2):242–7.
Jeha 2005
Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney
S, et al.Efficacy and safety of rasburicase, a recombinant
urate oxidase (elitek), in the management of malignancy-
associated hyperuricemia in pediatric and adult patients:
final results of a multicenter compassionate use trial.
Leukemia 2005;19(1):34–8.
Lascombes 1998
Lascombes F, Sommelet D, Gebhard F, Leverger G, Schaison
G, Pinkerton R, et al.High efficacy of recombinant urate
oxidase in prevention of renal failure related to tumor lysis
syndrome. Blood 1998;92(Suppl 1):237b.
Lee 2003
Lee AC, Li CH, So KT, Chan R. Treatment of impending
tumor lysis with single-dose rasburicase. Annals of
Pharmacotherapy 2003;37(11):1614–7.
Liu 2005
Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of
rasburicase is sufficient for the treatment of hyperuricemia
in patients receiving chemotherapy. Leukemia Research
2005;29(4):463–5.
McDonnell 2006
McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall
PD. Single-dose rasburicase 6 mg in the management of
tumor lysis syndrome in adults. Pharmacotherapy 2006;26
(6):806–12.
Navolanic 2003
Navolanic PM, Pui CH, Larson RA, Bishop MR, Pearce
TE, Cairo MS, et al.Elitek-Rasburicase: an effective means
to prevent and treat hyperuricemia associated with tumor
lysis syndrome, a Meeting Report, Dallas, Texas, January
2002. Leukemia 2003;17:499–514.
Pui 1997
Pui CH, Relling MV, Lascombes F, Harrison PL, Struxiano
A, Mondesir JM, et al.Urate oxidase in prevention and
treatment of hyperuricemia associated with lymphoid
malignancies. Leukemia 1997;11(11):1813–6.
Pui 2001a
Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger
G, Camitta B, et al.Recombinant urate oxidase for the
prophylaxis or treatment of hyperuricemia in patients with
leukemia or lymphoma. Journal of Clinical Oncology 2001;
19(3):697–704.
Pui 2001b
Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate
oxidase (rasburicase) in the prevention and treatment of
malignancy-associated hyperuricemia in pediatric and adult
patients: results of a compassionate-use trial. Leukemia
2001;15(10):1505–9.
Rampello 2006
Rampello E, Fricia T, Malaguarnera M. The management
of tumor lysis syndrome. Nature Clinical Practice Oncology
2006;3(8):438–47.
RevMan 2008
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.0. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2008.
Sanofi 2005
Sanofi-Synthelabo. Elitek (rasburicase) product monograph.
New York: Sanofi, 2005.
Shin 2006
Shin HY, Kang HJ, Park ES, Choi HS, Ahn HS, Kim SY, et
al.Recombinant urate oxidase (rasburicase) for the treatment
of hyperuricemia in pediatric patients with hematologic
malignancies: results of a compassionate prospective
multicenter study in Korea. Pediatric Blood and Cancer
2006;46(4):439–45.
Tosi 2008
Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E,
et al.Consensus conference on the management of tumor
lysis syndrome. Haematologica 2008;93:1877–85.
Trifilio 2006
Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid
K, et al.Reduced-dose rasburicase (recombinant xanthine
oxidase) in adult cancer patients with hyperuricemia. Bone
Marrow Transplantation 2006;37(11):997–1001.
Wang 2006
Wang LY, Shih LY, Chang H, Jou ST, Lin KH, Yeh TC,
et al.Recombinant urate oxidase (rasburicase) for the
prevention and treatment of tumor lysis syndrome in
patients with hematologic malignancies. Acta Haematologica
2006;115(1-2):35–8.
Yim 2003
Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for
the treatment and prevention of hyperuricemia. Annals of
Pharmacotherapy 2003;37(7-8):1047–54.
∗ Indicates the major publication for the study
21Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Goldman 2001
Methods Design: RCT
Randomization method: stratified randomization, computer-generated randomization code
Stratification factor: according to uric acid level (< 8 mg/dL or >= 8 mg/dL)
Participants Inclusion criteria: pediatric patients < 18 years with leukemia and lymphoma deemed to have a high
risk of tumor lysis syndrome: Murphy stage III or IV non-Hodgkin’s lymphoma, ALL with WBC
>= 25,000/uL, childhood lymphoma or leukemia with uric acid level of >= 8 mg/dL. Patients must
receive chemotherapeutic agents not investigational in nature, with minimum life expectancy of 4
weeks, and ECOG performance scale <= 3 or Karnofsky scale >= 30%
Exclusion criteria: patients previously treated with rasburicase or Uricozyme, treatment with allop-
urinol within 7 days, significant history of documented asthma, atopy, or G6PD deficiency
Number of subjects (intervention/comparison): 27/25
Number of boys (intervention/comparison): 16/18
Age (intervention/comparison): (mean) 7.1 (range 0.3 to 17)/7.8 (range 0.5 to 16) years
Underlying hematological malignancies (intervention/comparison): leukaemia 20/9; lymphoma 7/
6
Baseline creatinine (intervention/comparison): (mean) 0.6 (SD 0.33)/0.61 (SD 0.3) mg/dL
Baseline uric acid (intervention/comparison): (mean) 7.7 (SD 3.5)/6.8 (SD 3.4) mg/dL
Baseline potassium (intervention/comparison): (mean) 4.18 (SD 0.71)/3.85 (SD 0.52) mg/dL
Baseline phosphate (intervention/comparison): (mean) 4.62 (SD 1.39)/4.15 (SD 1.11) mg/dL
Baseline calcium (intervention/comparison): (mean) 8.92 (SD 0.74)/8.67 (SD 0.7) mg/dL
Baseline LDH (intervention/comparison): (mean) 1599 (SD 1022)/1393 (SD 1438) U/L
Baseline WBC (intervention/comparison): (mean) 83.2 (SD 81)/91 (SD 115) x109/L
Interventions Intervention (type of urate oxidase): rasburicase
Comparison (type of control): allopurinol
Treatment regime in intervention group: rasburicase 0.2 mg/kg ivi over 30 minutes daily for 5 to 7
days
Treatment regime in comparison group: allopurinol 300 mg/m2 /day or 10 mg/kg/day divided
every 8 hours for 5 to 7 days
Co-interventions: hydration 3 L/m2/day, iv sodium bicarbonate at investigator’s discretion
Outcomes All cause mortality
Mortality due to tumor lysis syndrome
Incidence of renal failure requiring renal replacement therapy
Frequency of normalization of serum uric acid level
Area under curve (AUC) of serum uric acid level
Frequency of adverse effects (hemolysis)
Notes Duration of follow up: 2 weeks
Number of drop-outs (intervention/comparison): 1 (hemolysis)/3 (2 died, 1 did not start chemo-
therapy)
Potential confounders were not described or adjusted
The 2 groups may not be comparable at baseline because serum uric acid level was higher in the
treatment group
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Goldman 2001 (Continued)
Whether outcomes were clearly defined: yes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes “Via telephone entry, treatment (rasburicase or
allopurinol) was randomly allocated to patients
according to a computer-generated randomiza-
tion code schema.”
Blinding of care providers? No Care providers know which treatment a subject
was allocated
Blinding of patients? No Patients know which treatment they were allo-
cated
Blinding of outcome assessors? Unclear This was not mentioned
Intention-to-treat analysis? Yes Although not specifically mentioned, the pa-
tients were analyzed according to the group they
were allocated to
Completeness of follow-up? No 4% of patients in the treatment group and 12%
of patients in the control group did not complete
treatment or follow up
Randomization? Yes “...treatment (rasburicase or allopurinol) was
randomly allocated to patients according
to a computer-generated randomization code
schema”
Kikuchi 2009
Methods Design: RCT
Randomization method: central randomization, details not available
Stratification factor: baseline body weight (< 10 or >= 10 kg)
Participants Inclusion criteria: pediatric patients < 18 years with newly diagnosed hematological malignancies
with hyperuricemia (uric acid > 7.5 mg/dL for patients >= 13 years; uric acid > 6.5 mg/dL for
patients < 13 years) or with a high tumor burden (defined as non-Hodgkin’s lymphoma stage IV;
NHL stage III with >= 1 lymph node or mass > 5 cm or LDH >= 3 times upper limit of normal)
or acute leukemia with WBC >= 50,000/mm3 and LDH >= 3 times upper limit of normal
ECOG performance scale <= 3 or Lansky score >= 30
Life expectancy >= 45 days
Exclusion criteria: administration of allopurinol within 72 hours, known history of severe allergy
and/or severe asthma, low birth weight (< 2500 g) or gestational age < 37 weeks, previous therapy
with urate oxidase, positive HBsAg, HCV antibodies, HIV-1 or HIV-2 antibodies, severe disorders
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Kikuchi 2009 (Continued)
of the liver or kidney (ALT > 5 times upper limit of normal, total bilirubin > 3 times upper
limit of normal, creatinine > 3 times upper limit of normal), uncontrollable infection including
viral infection, G6PD deficiency, known family history of G6PD deficiency, known history of
methemoglobinemia and hemolysis
Number of subjects (low-dose group/high-dose group): 15/15
Number of boys (low-dose group/high-dose group): 9/10
Age (low-dose group/high-dose group): (median) 11 (range 1 to 17)/7 (range 0 to 16) years
Underlying hematological malignancies (low-dose group/high-dose group): acute leukemia 9/13;
lymphoma 6/2
Baseline hyperuricemia (low-dose group/high-dose group): 8/5
Baseline creatinine (low-dose group/high-dose group): (mean) 52.3 (SD 22.6)/44.4 (SD 19.1)
micromol/L
Interventions Intervention (type of urate oxidase): rasburicase in both groups (0.15 mg/kg versus 0.2 mg/kg)
Treatment regime in low-dose group: rasburicase 0.15 mg/kg ivi over 30 minutes daily for 5 days
Treatment regime in high-dose group: rasburicase 0.15 mg/kg ivi over 30minutes daily for 5 days
Co-interventions: chemotherapy starts 4 to 24 hours after the first dose of rasburicase in both groups
Outcomes All-cause mortality
Mortality due to tumor lysis syndrome
Incidence of renal failure requiring renal replacement therapy
Frequency of normalization of serum uric acid level
Rate of uric acid inhibition
Frequency of adverse events
Notes Duration of follow up: 5 weeks
Number of drop-outs (low-dose group/high-dose group): 0/1 (lack of WBC result at baseline)
The 2 groups may not be comparable at baseline because body weight was higher in the low-dose
group; baseline hyperuricemia and diagnosis of lymphoma were more frequent in the low-dose
group
Whether outcomes were clearly defined: yes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear This was not mentioned
Blinding of care providers? No Care providers know which treatment a subject
was allocated
Blinding of patients? No Patients know which treatment they were allo-
cated
Blinding of outcome assessors? No Outcome assessors know which treatment pa-
tients were assigned as this was an open-label trial
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Kikuchi 2009 (Continued)
Intention-to-treat analysis? Yes Although not specifically mentioned, the pa-
tients were analyzed according to the group they
were allocated to
Completeness of follow-up? No 6.7% of each group of patients did not complete
treatment of follow up
Randomization? Yes Patients were randomly allocated to the 2 treat-
ment groups by central randomization
Patte 2002
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: pediatric patients with stage III and IV B-cell NHL or L3 ALL treated with the
LMB89 protocol (intervention group), pediatric patients with stage IV B-cell NHL or ALL treated
with UKCCSG protocol (comparison group 1), or pediatric patients with stage IV B-cell NHL or
ALL treated with POG protocol (comparison group 2)
Exclusion criteria: patients not treated in France excluded from intervention group
Number of subjects (intervention/comparison): 152/63/123
Number of boys (intervention/comparison): not available
Age (intervention/comparison): not available
Underlying hematological malignancies: only data for intervention group available: B-NHL stage
III 257/410; B-NHL stage IV 57/410; L3 ALL 96/410
Baseline renal failure (intervention/comparison): 21/410/not available
Baseline LDH (intervention/comparison): (>= 2 x normal) 234/410/not available
Interventions Intervention (type of urate oxidase): Uricozyme
Comparison (type of control): allopurinol
Treatment regime in intervention group: Uricozyme 50 to 100 U/kg/day for 5 to 7 days
Treatment regime in comparison group: not available
Co-interventions: intervention group: alkaline hyperhydration 3 L/m2/day to obtain urine output
100 to 120 ml/m2/hour and urine pH 7; not stated in comparison groups
Outcomes Mortality due to tumor lysis syndrome
Incidence of renal failure requiring renal replacement therapy
Notes Potential confounders were not described or adjusted
Comparability of the treatment groups at baseline is uncertain because baseline characteristics of
comparison groups are not available
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No This is not a randomized controlled trial and no
allocation concealment was used
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Patte 2002 (Continued)
Blinding of care providers? No Blinding was not used
Blinding of patients? No Blinding was not used
Blinding of outcome assessors? No Blinding was not used
Intention-to-treat analysis? Yes Although not specifically mentioned, the pa-
tients were analyzed according to the group they
were allocated to
Completeness of follow-up? Yes The outcome data were complete for the groups
of patients analyzed
Randomization? No Control groups were retrospective cohorts
treated on different chemotherapy protocols and
allopurinol
Renyi 2007
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: pediatric patients aged 6 months to 18 years with a recent diagnosis of B-cell
lineage ALL with an initial WBC >= 25,000/uL, or high-grade non-Hodgkin’s lymphoma, or any
type of ALL or NHL with a plasma uric acid >= 480 mmol/L and LDH > 500 IU/L, or either a
creatinine or an LDH concentration > twice upper normal limit
Exclusion criteria: history of clinically significant atopic allergy, bronchial asthma, G6PD deficiency
or any type of hemolytic anemia, previous treatment with rasburicase or non-recombinant urate
oxidase, hypersensitivity reaction against ingredients of the present preparation used in the study,
participation in another drug experiment, pregnancy or lactation
Number of subjects (intervention/comparison): 12/14
Number of boys (intervention/comparison): 6/6
Age (intervention/comparison): (median) 4.5/6
Underlying hematological malignancies: leukaemia 8/13; lymphoma 4/1
Baseline creatinine (intervention/comparison): median 65 (range 32 to 85)/80 (range 17 to 353)
umol/L
Baseline uric acid (intervention/comparison): median 323 (range 139 to 1059)/207 (range 51 to
785) umol/L
Baseline potassium (intervention/comparison): N/A
Baseline phosphate (intervention/comparison): median 1.32 (range 0.97 to 1.64)/1.62 (range 0.98
to 1.33) mmol/L
Baseline LDH (intervention/comparison): 1909 (range 497 to 9760)/3193 (236 to 20,560) U/L
Baseline WBC (intervention/comparison): 51.8 (range 2 to 651)/56 (range 0.4 to 551) x109/L
Interventions Intervention (type of urate oxidase): rasburicase
Comparison (type of control): allopurinol
Treatment regime in intervention group: rasburicase 0.2 mg/kg ivi over 30 minutes daily for 5 days
from day 1 of anti-neoplastic treatment
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Renyi 2007 (Continued)
Treatment regime in comparison group: allopurinol 300 mg/m2 /day or 10 mg/kg/day divided
every 8 hours for 5 to 7 days
Co-interventions: hydration 3 L/m2/day, iv sodium bicarbonate 20 to 40 mmol/L to maintain
urine pH 6.5 to 7
Outcomes All-cause mortality
Mortality due to tumor lysis syndrome
Incidence of renal failure requiring renal replacement therapy
Serial uric acid levels
Area under curve (AUC) of serum uric acid level
Frequency of adverse effects
Notes Duration of follow up: 12 days
Potential confounders were not described or adjusted
The 2 groups may not be comparable at baseline because the treatment group has more patients
with lymphoma, higher uric acid level, lower LDH level, lower serum creatinine and phosphorus
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No This is not a randomized controlled trial and no
allocation concealment was used
Blinding of care providers? No Blinding was not used
Blinding of patients? No Blinding was not used
Blinding of outcome assessors? No Blinding was not used
Intention-to-treat analysis? Yes Although not specifically mentioned, the pa-
tients were analyzed according to the group they
were allocated to
Completeness of follow-up? No Serum uric acid data at 24 to 288 hours post-
treatment were missing in 6 to 12 patients (43%
to 86%)
Randomization? No Historical controls were used
Wossmann 2003
Methods Design: CCT
Randomization method: not used
Stratification factor: not applicable
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Wossmann 2003 (Continued)
Participants Inclusion criteria: pediatric patients <= 18 years with B-ALL or stage III and IV B-NHL and LDH
>= 500 U/L treated in the trials NHL-BFM 90 and 95, during the period November 1997 to
December 2001 (intervention group) or April 1990 to March 1996 (comparison group)
Exclusion criteria : nil
Number of subjects (intervention/comparison): 130/218
Number of boys (intervention/comparison): N/A
Age (intervention/comparison): N/A
Underlying hematological malignancies: B-ALL 53/78; B-NHL 77/140
Baseline LDH (intervention/comparison): (> 1000 U/L) 49.6%/47.2%
Interventions Intervention (type of urate oxidase): Uricozyme
Comparison (type of control): allopurinol + alkalinization
Treatment regime in intervention group: Uricozyme 3 x 50 U/kg/day
Treatment regime in comparison group: allopurinol 10 mg/kg/day + alkalinization to maintain
urine pH 7
Co-interventions: hydration 3 to 4.5 L/m2/day
Outcomes Incidence of clinical tumor lysis syndrome
All-cause mortality
Incidence of renal failure requiring renal replacement therapy
Notes Potential confounders were not described or adjusted
The 2 groups may not be comparable at baseline because the treatment group had fewer patients
who were critically ill or had complications after initial surgery
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No This is not a randomized controlled trial and no
allocation concealment was used
Blinding of care providers? No Blinding was not used
Blinding of patients? No Blinding was not used
Blinding of outcome assessors? No Blinding was not used
Intention-to-treat analysis? Yes Although not specifically mentioned, the pa-
tients were analyzed according to the group they
were allocated to
Completeness of follow-up? Yes The outcome data were complete for the groups
of patients analyzed
Randomization? No Historical controls were used
CCT: controlled clinical trial
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ECOG: Eastern Cooperative Oncology Group
G6PD: glucose-6-phosphate dehydrogenase deficiency
iv: intravenous
LDH: lactate dehydrogenase
RCT: randomized controlled trial
SD: standard deviation
WBC: white blood cell (count)
ALL: acute lymphoblastic leukemia
ALT: alanine aminotransferase
HCV: hepatitis C virus
HBsAg: hepatitis B virus surface antigen
NHL: non-Hodgkin lymphoma
ivi: intravenous infusion
UKCCSG: United Kingdom Children’s Cancer Study Group
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D A T A A N D A N A L Y S E S
Comparison 1. Urate oxidase compared with allopurinol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of clinical tumor lysis
syndrome
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 CCT 1 348 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.44, 1.33]
2 Incidence of clinical tumor lysis
syndrome in B-ALL subgroup
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 CCT 1 131 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.18, 1.18]
3 All-cause mortality 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 RCT 1 52 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 3.69]
3.2 CCT 2 374 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 3.42]
4 Mortality due to tumor lysis
syndrome
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 RCT 1 52 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.2 CCT 2 364 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.00, 0.89]
5 Renal failure requiring renal
replacement therapy
4 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5.1 RCT 1 Risk Ratio (M-H, Random, 95% CI) Not estimable
5.2 CCT 3 Risk Ratio (M-H, Random, 95% CI) Not estimable
6 Renal failure requiring renal
replacement therapy in B-ALL
subgroup
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 CCT 1 131 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.06, 1.05]
7 Normalization of serum uric
acid level at 4 hours
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 RCT 1 19 Risk Ratio (M-H, Fixed, 95% CI) 19.09 [1.28, 285.41]
8 AUC of serum uric acid level at
96 hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 RCT 1 52 Mean Difference (IV, Fixed, 95% CI) -201.0 [-258.05, -
143.95]
9 AUC of serum uric acid level at
96 hours in leukemia patients
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 RCT 1 39 Mean Difference (IV, Fixed, 95% CI) -220.0 [-286.67, -
153.33]
10 AUC of serum uric acid level at
96 hours in lymphoma patients
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 RCT 1 13 Mean Difference (IV, Fixed, 95% CI) -132.0 [-185.47, -
78.53]
11 AUC of serum uric acid level
at 96 hours in hyperuricemic
patients
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 RCT 1 52 Mean Difference (IV, Fixed, 95% CI) -278.0 [-335.68, -
220.32]
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12 AUC of serum uric acid level
at 96 hours in normouricemic
patients
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 RCT 1 52 Mean Difference (IV, Fixed, 95% CI) -240.00 [-320.72, -
159.28]
13 Serum uric acid level at 24
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 CCT 1 18 Mean Difference (IV, Fixed, 95% CI) 121.67 [-122.47,
365.81]
14 Serum uric acid level at 48
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 CCT 1 14 Mean Difference (IV, Fixed, 95% CI) -216.92 [-542.68,
108.84]
15 Serum uric acid level at 72
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 CCT 1 15 Mean Difference (IV, Fixed, 95% CI) -98.33 [-170.66, -
26.00]
16 Serum uric acid level at 120
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
16.1 CCT 1 14 Mean Difference (IV, Fixed, 95% CI) -61.12 [-133.47,
11.23]
17 Serum uric acid level at 168
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 CCT 1 16 Mean Difference (IV, Fixed, 95% CI) -103.67 [-177.00, -
28.34]
18 Serum uric acid level at 288
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
18.1 CCT 1 20 Mean Difference (IV, Fixed, 95% CI) -47.63 [-148.84,
53.58]
19 Frequency of adverse events 1 52 Risk Ratio (M-H, Fixed, 95% CI) 2.79 [0.12, 65.38]
19.1 RCT 1 52 Risk Ratio (M-H, Fixed, 95% CI) 2.79 [0.12, 65.38]
Comparison 2. High-dose rasburicase compared to low-dose rasburicase
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality due to tumor lysis
syndrome
1 30 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.1 RCT 1 30 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 All-cause mortality 1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.58]
2.1 RCT 1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.58]
3 Normalization of serum uric acid 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.89, 1.28]
3.1 RCT 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.89, 1.28]
4 Percentage reduction in serum
uric acid level at 4 hours
1 29 Mean Difference (IV, Fixed, 95% CI) 8.10 [-0.99, 17.19]
4.1 RCT 1 29 Mean Difference (IV, Fixed, 95% CI) 8.10 [-0.99, 17.19]
5 Frequency of adverse events 1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.11, 2.33]
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5.1 RCT 1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.11, 2.33]
Analysis 1.1. Comparison 1 Urate oxidase compared with allopurinol, Outcome 1 Incidence of clinical
tumor lysis syndrome.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 1 Incidence of clinical tumor lysis syndrome
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Wossmann 2003 16/130 35/218 100.0 % 0.77 [ 0.44, 1.33 ]
Subtotal (95% CI) 130 218 100.0 % 0.77 [ 0.44, 1.33 ]
Total events: 16 (Treatment), 35 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
0.05 0.2 1 5 20
Favours treatment Favours control
Analysis 1.2. Comparison 1 Urate oxidase compared with allopurinol, Outcome 2 Incidence of clinical
tumor lysis syndrome in B-ALL subgroup.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 2 Incidence of clinical tumor lysis syndrome in B-ALL subgroup
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Wossmann 2003 5/53 16/78 100.0 % 0.46 [ 0.18, 1.18 ]
Subtotal (95% CI) 53 78 100.0 % 0.46 [ 0.18, 1.18 ]
Total events: 5 (Treatment), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.3. Comparison 1 Urate oxidase compared with allopurinol, Outcome 3 All-cause mortality.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 3 All-cause mortality
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Goldman 2001 0/27 2/25 0.19 [ 0.01, 3.69 ]
Subtotal (95% CI) 27 25 0.19 [ 0.01, 3.69 ]
Total events: 0 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 CCT
Renyi 2007 0/12 0/14 0.0 [ 0.0, 0.0 ]
Wossmann 2003 0/130 4/218 0.19 [ 0.01, 3.42 ]
Subtotal (95% CI) 142 232 0.19 [ 0.01, 3.42 ]
Total events: 0 (Treatment), 4 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
0.02 0.1 1 10 50
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Analysis 1.4. Comparison 1 Urate oxidase compared with allopurinol, Outcome 4 Mortality due to tumor
lysis syndrome.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 4 Mortality due to tumor lysis syndrome
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Goldman 2001 0/27 0/25 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 27 25 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 CCT
Patte 2002 0/152 11/186 0.05 [ 0.00, 0.89 ]
Renyi 2007 0/12 0/14 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 164 200 0.05 [ 0.00, 0.89 ]
Total events: 0 (Treatment), 11 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.042)
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Analysis 1.5. Comparison 1 Urate oxidase compared with allopurinol, Outcome 5 Renal failure requiring
renal replacement therapy.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 5 Renal failure requiring renal replacement therapy
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 RCT
Goldman 2001 0/27 1/25 0.31 [ 0.01, 7.26 ]
2 CCT
Patte 2002 4/152 38/186 0.13 [ 0.05, 0.35 ]
Renyi 2007 0/12 1/14 0.38 [ 0.02, 8.65 ]
Wossmann 2003 8/130 20/218 0.67 [ 0.30, 1.48 ]
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Analysis 1.6. Comparison 1 Urate oxidase compared with allopurinol, Outcome 6 Renal failure requiring
renal replacement therapy in B-ALL subgroup.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 6 Renal failure requiring renal replacement therapy in B-ALL subgroup
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Wossmann 2003 2/53 12/78 100.0 % 0.25 [ 0.06, 1.05 ]
Subtotal (95% CI) 53 78 100.0 % 0.25 [ 0.06, 1.05 ]
Total events: 2 (Treatment), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.058)
0.1 0.2 0.5 1 2 5 10
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Analysis 1.7. Comparison 1 Urate oxidase compared with allopurinol, Outcome 7 Normalization of serum
uric acid level at 4 hours.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 7 Normalization of serum uric acid level at 4 hours
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Goldman 2001 10/10 0/9 100.0 % 19.09 [ 1.28, 285.41 ]
Subtotal (95% CI) 10 9 100.0 % 19.09 [ 1.28, 285.41 ]
Total events: 10 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.033)
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.8. Comparison 1 Urate oxidase compared with allopurinol, Outcome 8 AUC of serum uric acid
level at 96 hours.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 8 AUC of serum uric acid level at 96 hours
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 27 128 (70) 25 329 (129) 100.0 % -201.00 [ -258.05, -143.95 ]
Subtotal (95% CI) 27 25 100.0 % -201.00 [ -258.05, -143.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.91 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Urate oxidase compared with allopurinol, Outcome 9 AUC of serum uric acid
level at 96 hours in leukemia patients.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 9 AUC of serum uric acid level at 96 hours in leukemia patients
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 20 141 (75) 19 361 (129) 100.0 % -220.00 [ -286.67, -153.33 ]
Subtotal (95% CI) 20 19 100.0 % -220.00 [ -286.67, -153.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Urate oxidase compared with allopurinol, Outcome 10 AUC of serum uric
acid level at 96 hours in lymphoma patients.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 10 AUC of serum uric acid level at 96 hours in lymphoma patients
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 7 92 (41) 6 224 (55) 100.0 % -132.00 [ -185.47, -78.53 ]
Subtotal (95% CI) 7 6 100.0 % -132.00 [ -185.47, -78.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.84 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Urate oxidase compared with allopurinol, Outcome 11 AUC of serum uric
acid level at 96 hours in hyperuricemic patients.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 11 AUC of serum uric acid level at 96 hours in hyperuricemic patients
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 27 162 (87) 25 440 (121) 100.0 % -278.00 [ -335.68, -220.32 ]
Subtotal (95% CI) 27 25 100.0 % -278.00 [ -335.68, -220.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.45 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Urate oxidase compared with allopurinol, Outcome 12 AUC of serum uric
acid level at 96 hours in normouricemic patients.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 12 AUC of serum uric acid level at 96 hours in normouricemic patients
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 27 108 (51) 25 348 (200) 100.0 % -240.00 [ -320.72, -159.28 ]
Subtotal (95% CI) 27 25 100.0 % -240.00 [ -320.72, -159.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.83 (P < 0.00001)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
Favours treatment Favours control
38Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.13. Comparison 1 Urate oxidase compared with allopurinol, Outcome 13 Serum uric acid level
at 24 hours.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 13 Serum uric acid level at 24 hours
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
Renyi 2007 12 367 (200.91) 6 245.33 (270.02) 100.0 % 121.67 [ -122.47, 365.81 ]
Subtotal (95% CI) 12 6 100.0 % 121.67 [ -122.47, 365.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Urate oxidase compared with allopurinol, Outcome 14 Serum uric acid level
at 48 hours.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 14 Serum uric acid level at 48 hours
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
Renyi 2007 12 58.58 (82.28) 2 275.5 (232.64) 100.0 % -216.92 [ -542.68, 108.84 ]
Subtotal (95% CI) 12 2 100.0 % -216.92 [ -542.68, 108.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Urate oxidase compared with allopurinol, Outcome 15 Serum uric acid level
at 72 hours.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 15 Serum uric acid level at 72 hours
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
Renyi 2007 12 39.67 (38.04) 3 138 (61.02) 100.0 % -98.33 [ -170.66, -26.00 ]
Subtotal (95% CI) 12 3 100.0 % -98.33 [ -170.66, -26.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0077)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Urate oxidase compared with allopurinol, Outcome 16 Serum uric acid level
at 120 hours.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 16 Serum uric acid level at 120 hours
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
Renyi 2007 12 25.88 (28.32) 2 87 (50.91) 100.0 % -61.12 [ -133.47, 11.23 ]
Subtotal (95% CI) 12 2 100.0 % -61.12 [ -133.47, 11.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.098)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Urate oxidase compared with allopurinol, Outcome 17 Serum uric acid level
at 168 hours.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 17 Serum uric acid level at 168 hours
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
Renyi 2007 12 84.83 (63.27) 4 188.5 (67.63) 100.0 % -103.67 [ -179.00, -28.34 ]
Subtotal (95% CI) 12 4 100.0 % -103.67 [ -179.00, -28.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.70 (P = 0.0070)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Urate oxidase compared with allopurinol, Outcome 18 Serum uric acid level
at 288 hours.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 18 Serum uric acid level at 288 hours
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
Renyi 2007 12 139.25 (88.36) 8 186.88 (127) 100.0 % -47.63 [ -148.84, 53.58 ]
Subtotal (95% CI) 12 8 100.0 % -47.63 [ -148.84, 53.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Urate oxidase compared with allopurinol, Outcome 19 Frequency of adverse
events.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 19 Frequency of adverse events
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Goldman 2001 1/27 0/25 100.0 % 2.79 [ 0.12, 65.38 ]
Total (95% CI) 27 25 100.0 % 2.79 [ 0.12, 65.38 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 High-dose rasburicase compared to low-dose rasburicase, Outcome 1 Mortality
due to tumor lysis syndrome.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 2 High-dose rasburicase compared to low-dose rasburicase
Outcome: 1 Mortality due to tumor lysis syndrome
Study or subgroup High dose Low dose Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Kikuchi 2009 0/15 0/15 0.0 [ 0.0, 0.0 ]
Total (95% CI) 15 15 0.0 [ 0.0, 0.0 ]
Total events: 0 (High dose), 0 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.2. Comparison 2 High-dose rasburicase compared to low-dose rasburicase, Outcome 2 All-cause
mortality.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 2 High-dose rasburicase compared to low-dose rasburicase
Outcome: 2 All-cause mortality
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Kikuchi 2009 0/15 1/15 100.0 % 0.33 [ 0.01, 7.58 ]
Total (95% CI) 15 15 100.0 % 0.33 [ 0.01, 7.58 ]
Total events: 0 (High dose), 1 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 High-dose rasburicase compared to low-dose rasburicase, Outcome 3
Normalization of serum uric acid.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 2 High-dose rasburicase compared to low-dose rasburicase
Outcome: 3 Normalization of serum uric acid
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Kikuchi 2009 14/14 14/15 100.0 % 1.07 [ 0.89, 1.28 ]
Total (95% CI) 14 15 100.0 % 1.07 [ 0.89, 1.28 ]
Total events: 14 (High dose), 14 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 High-dose rasburicase compared to low-dose rasburicase, Outcome 4
Percentage reduction in serum uric acid level at 4 hours.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 2 High-dose rasburicase compared to low-dose rasburicase
Outcome: 4 Percentage reduction in serum uric acid level at 4 hours
Study or subgroup High dose Low dose Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Kikuchi 2009 14 92.9 (7.9) 15 84.8 (16) 100.0 % 8.10 [ -0.99, 17.19 ]
Total (95% CI) 14 15 100.0 % 8.10 [ -0.99, 17.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 High-dose rasburicase compared to low-dose rasburicase, Outcome 5
Frequency of adverse events.
Review: Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer
Comparison: 2 High-dose rasburicase compared to low-dose rasburicase
Outcome: 5 Frequency of adverse events
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Kikuchi 2009 2/15 4/15 100.0 % 0.50 [ 0.11, 2.33 ]
Total (95% CI) 15 15 100.0 % 0.50 [ 0.11, 2.33 ]
Total events: 2 (High dose), 4 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
PubMed interface used
1. Urate oxidase
urate oxidase OR uricase OR uricas* OR oxidase, urate OR EC 1.7.3.3. OR rasburicase OR rasburicas* OR elitek OR fasturtec OR
fasturt* OR uox
2. Children
infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies OR neonat* OR child OR child* OR
schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen*
OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR
puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR
nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary
school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy OR schools, nursery
OR infant, newborn
3. Cochrane RCT and CCT
(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh]
OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (“clinical trial” [tw])
OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (placebos [mh] OR placebo*
[tw] OR random* [tw] OR research design [mh:NoExp]OR comparative study [mh]OR evaluation studies [mh]OR follow-up studies
[mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT humans
[mh]))
4. 1 AND 2 AND 3
Appendix 2. EMBASE search strategy
1. Urate oxidase
1. urate oxidase.mp. or Urate Oxidase/
2. (rasburicase or uox).mp.
3. (uricase or elitek).mp.
4. (9002-12-4 or 352311-12-7).rn. or EC 1733.mp.
5. (uricas$ or rasburicas$ or fasturtec or fasturt$).mp.
6. or/1-5
2. Children
1. infant/ or infancy/ or newborn/ or baby/ or child/ or preschool child/ or school child/
2. adolescent/ or juvenile/ or boy/ or girl/ or puberty/ or prepuberty/ or pediatrics/
3. primary school/ or high school/ or kindergarten/ or nursery school/ or school/
4. or/1-3
5. (infant$ or (newborn$ or new born$) or (baby or baby$ or babies) or neonate$).mp.
6. (child$ or (school child$ or schoolchild$) or (school age$ or schoolage$) or (pre school$ or preschool$)).mp.
7. (kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$).mp.
8. (minors$ or (under ag$ or underage$) or juvenil$ or youth$).mp.
9. (puber$ or pubescen$ or prepubescen$ or prepubert$).mp.
10. (pediatric$ or paediatric$ or peadiatric$).mp.
11. (school or schools or (high school$ or highschool$) or primary school$ or nursery school$ or elementary school or secondary
school$ or kindergar$).mp.
12. or/5-11
13. 4 or 12
3. RCT/CCT
1. Clinical Trial/
2. Controlled Study/
3. Randomized Controlled Trial/
4. Double Blind Procedure/
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5. Single Blind Procedure/
6. Comparative Study/
7. RANDOMIZATION/
8. Prospective Study/
9. PLACEBO/
10. Phase 2 Clinical Trial/
11. phase 3 clinical study.mp.
12. phase 4 clinical study.mp.
13. Phase 3 Clinical Trial/
14. Phase 4 Clinical Trial/
15. or/1-14
16. allocat$.mp.
17. blind$.mp.
18. control$.mp.
19. placebo$.mp.
20. prospectiv$.mp.
21. random$.mp.
22. ((singl$ or doubl$ or trebl$ or tripl$) and (blind$ or mask$)).mp.
23. (versus or vs).mp.
24. (randomized controlled trial$ or randomised controlled trial$).mp.
25. controlled clinical trial$.mp.
26. clinical trial$.mp.
27. or/16-27
28. Human/
29. Nonhuman/
30. ANIMAL/
31. Animal Experiment/
32. or/29-31
33. 32 not 28
34. (15 or 27) not 33
4. 1 and 2 and 3 (Urate oxidase AND Children AND RCT)
Appendix 3. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
urate oxidase OR uricase OR uricas* rasburicase OR rasburicas* OR elitek OR fasturtec OR fasturt* OR uox
Appendix 4. CINAHL search strategy
1. Urate oxidase
urate oxidase OR rasburicase OR uox OR uricase OR elitek OR fasfurtec
2. Children
neonate OR infant OR newborn OR baby OR child OR preschool OR school OR adolescent OR juvenile OR boy OR girl OR
puberty OR pediatric OR kindergarten OR nursery OR kid OR minors
3. RCT/CCT
trial OR control OR placebo OR random OR prospective study OR comparative study
In the final search the three searches were combined: 1 AND 2 AND 3
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Appendix 5. Abbreviations
CCT: controlled clinical trial; RCT: randomized controlled trial; mh:Medical Subject Heading (MeSH) term; mp: mapping alias (title,
original title, abstract, name of substance word, subject heading word); pt: publication type; rn: Chemical Abstracts Service (CAS)
registry number; tw: text word
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Allopurinol [therapeutic use]; Antimetabolites [therapeutic use]; Controlled Clinical Trials as Topic; Neoplasms [drug therapy]; Ran-
domized Controlled Trials as Topic; Renal Insufficiency [prevention & control]; Tumor Lysis Syndrome [mortality; ∗prevention &
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MeSH check words
Child; Humans
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